{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:48:44Z","timestamp":1774529324843,"version":"3.50.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.ucl.2011.02.006","type":"journal-article","created":{"date-parts":[[2011,6,7]],"date-time":"2011-06-07T13:42:47Z","timestamp":1307454167000},"page":"195-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Peyronie\u2019s Disease: Review of Nonsurgical Treatment Options"],"prefix":"10.1016","volume":"38","author":[{"given":"Stephen M.","family":"Larsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence A.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ucl.2011.02.006_bib1","first-page":"337","article-title":"Sur quelques obstacles qui s'opposent a l'ejaculation naturelle de la semence","volume":"1","author":"de la Peyronie","year":"1743","journal-title":"Mem Acad Royale Chir"},{"key":"10.1016\/j.ucl.2011.02.006_bib2","first-page":"2284","article-title":"An animal model of Peyronie\u2019s like condition associated with an increase of transforming growth factor beta mRNA and protein expression","volume":"158","author":"El-Sakka","year":"1997","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2011.02.006_bib3","first-page":"1391","article-title":"Peyronie\u2019s disease is associated with an increase in transforming growth factor-beta protein expression","volume":"158","author":"El-Sakka","year":"1997","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2011.02.006_bib4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.ijir.3900874","article-title":"Peyronie\u2019s disease cell culture models: phenotypic, genotypic and functional analyses","volume":"14","author":"Mulhall","year":"2002","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.ucl.2011.02.006_bib5","first-page":"1330","article-title":"Peyronie\u2019s disease is associated with an HLA class II antigen, HLA-DQ5, implying an autoimmune etiology","volume":"156","author":"Nachtsheim","year":"1996","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2011.02.006_bib6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0090-4295(97)00333-6","article-title":"Immunologic findings in Peyronie\u2019s disease: a controlled study","volume":"50","author":"Schiavino","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2011.02.006_bib7","first-page":"1607","article-title":"Profibrotic role of myostatin in Peyronie\u2019s disease","volume":"5","author":"Cantini","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2011.02.006_bib8","first-page":"1284","article-title":"IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie\u2019s disease","volume":"6","author":"Ryu","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2011.02.006_bib9","first-page":"2447","article-title":"Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie\u2019s plaque fibroblasts","volume":"179","author":"Del Carlo","year":"2008","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2011.02.006_bib10","first-page":"485","article-title":"Defining the clinical characteristics of Peyronie\u2019s disease in young men","volume":"4","author":"Deveci","year":"2007","journal-title":"J\u00a0Sex Med"},{"issue":"1","key":"10.1016\/j.ucl.2011.02.006_bib11","first-page":"69","article-title":"Peyronie\u2019s disease: a study of its natural history and treatment with orthovoltage radiotherapy","volume":"114","author":"Furlow","year":"1975","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2011.02.006_bib12","first-page":"1376","article-title":"The natural history of Peyronie\u2019s disease","volume":"144","author":"Gelbard","year":"1990","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2011.02.006_bib13","first-page":"1075","article-title":"A\u00a0retrospective review of 307 men with Peyronie\u2019s disease","volume":"168","author":"Deveci","year":"2002","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2011.02.006_bib14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ncpuro0729","article-title":"The medical management of Peyronie\u2019s disease","volume":"4","author":"Akin-Olugbade","year":"2007","journal-title":"Nat Clin Pract Urol"},{"issue":"4","key":"10.1016\/j.ucl.2011.02.006_bib15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2165\/00003495-200767040-00004","article-title":"Pharmacological management of Peyronie\u2019s disease","volume":"67","author":"Trost","year":"2007","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ucl.2011.02.006_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1745-7262.2008.00351.x","article-title":"Non-surgical therapy of Peyronie\u2019s disease","volume":"10","author":"Taylor","year":"2008","journal-title":"Asian J Androl"},{"issue":"7","key":"10.1016\/j.ucl.2011.02.006_bib17","first-page":"2359","article-title":"The management of Peyronie\u2019s disease: evidence-based 2010 guidelines","volume":"7","author":"Ralph","year":"2010","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2011.02.006_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00007611-194802000-00017","article-title":"A\u00a0new concept in the treatment of Peyronie\u2019s disease","volume":"41","author":"Scott","year":"1948","journal-title":"South Med J"},{"key":"10.1016\/j.ucl.2011.02.006_bib19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.ijir.3900880","article-title":"Role of oxidative stress and antioxidants in Peyronie\u2019s disease","volume":"14","author":"Sikka","year":"2002","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.ucl.2011.02.006_bib20","first-page":"41","article-title":"Controlled clinical trial of Vitamin E in Peyronie\u2019s disease","volume":"9","author":"Pryor","year":"1983","journal-title":"Prog Reprod Biol"},{"issue":"4\u00a0Pt\u00a01","key":"10.1016\/j.ucl.2011.02.006_bib21","first-page":"1398","article-title":"Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie\u2019s disease: a double-blind, placebo controlled, randomized study","volume":"178","author":"Safarinejad","year":"2007","journal-title":"J\u00a0Urol"},{"issue":"22","key":"10.1016\/j.ucl.2011.02.006_bib22","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2011.02.006_bib23","series-title":"Basic and clinical pharmacology","article-title":"Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics & drugs used in gout","author":"Furst","year":"2001"},{"key":"10.1016\/j.ucl.2011.02.006_bib24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0090-4295(94)80155-X","article-title":"Is colchicine effective in Peyronie\u2019s disease? A pilot study","volume":"44","author":"Akkus","year":"1994","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2011.02.006_bib25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/sj.ijir.3900519","article-title":"Treatment of Peyronie\u2019s disease with oral colchicine: long term results and predictive parameters of successful outcome","volume":"12","author":"Kadioglu","year":"2000","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.ucl.2011.02.006_bib26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.ijir.3901185","article-title":"Therapeutic effects of colchicine in the management of Peyronie\u2019s disease: a randomized double-blind, placebo-controlled study","volume":"16","author":"Safarinejad","year":"2004","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.ucl.2011.02.006_bib27","first-page":"770","article-title":"Treatment of Peyronie\u2019s disease with potassium para-aminobenzoate (Potaba)","volume":"81","author":"Zarafonetis","year":"1959","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2011.02.006_bib28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2340\/00015555721518","article-title":"A\u00a0comparison of morphoea and lichen sclerosus et atrophicus in vitro: the effects of para-aminobenzoate on skin fibroblasts","volume":"72","author":"Griffiths","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ucl.2011.02.006_bib29","first-page":"205","article-title":"Randomized prospective placebo controlled therapy of Peyronie\u2019s disease (IPP) with Potaba (aminobenzoate potassium)","volume":"6","author":"Weidner","year":"1999","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2011.02.006_bib30","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.eururo.2004.12.022","article-title":"Potassium paraaminobenzoate (Potaba) in the treatment of Peyronie\u2019s disease: a prospective, placebo-controlled, randomized study","volume":"47","author":"Weidner","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2011.02.006_bib31","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1464-410X.1992.tb15836.x","article-title":"The treatment of Peyronie\u2019s disease with tamoxifen","volume":"70","author":"Ralph","year":"1992","journal-title":"Br J Urol"},{"key":"10.1016\/j.ucl.2011.02.006_bib32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/bjc.1990.307","article-title":"Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts","volume":"62","author":"Colletta","year":"1990","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ucl.2011.02.006_bib33","first-page":"2003","article-title":"Tamoxifen versus placebo in the treatment of Peyronie\u2019s disease","volume":"162","author":"Teloken","year":"1999","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2011.02.006_bib34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1464-410x.2001.02241.x","article-title":"Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie\u2019s disease: a preliminary report","volume":"88","author":"Biagiotti","year":"2001","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.ucl.2011.02.006_bib35","first-page":"2077","article-title":"Pentoxifylline attenuates transforming growth factor-\u03b21-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix","volume":"7","author":"Shindel","year":"2010","journal-title":"J\u00a0Sex Med"},{"issue":"5","key":"10.1016\/j.ucl.2011.02.006_bib36","first-page":"1787","article-title":"Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: interference in a TGF-beta1\/Smad-dependent mechanism and downregulation of AAT1","volume":"7","author":"Lin","year":"2010","journal-title":"J\u00a0Sex Med"},{"issue":"2","key":"10.1016\/j.ucl.2011.02.006_bib37","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1464-410X.2009.09041.x","article-title":"A\u00a0double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie\u2019s disease","volume":"106","author":"Safarinejad","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2011.02.006_bib38","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0090-4295(98)00582-2","article-title":"EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction","volume":"53","author":"Althof","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2011.02.006_bib39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00255956","article-title":"Collagenase for Peyronie\u2019s disease experimental studies","volume":"10","author":"Gelbard","year":"1982","journal-title":"Urol Res"},{"key":"10.1016\/j.ucl.2011.02.006_bib40","first-page":"280","article-title":"The use of collagenase in the treatment of Peyronie\u2019s disease","volume":"134","author":"Gelbard","year":"1985","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2011.02.006_bib41","first-page":"56","article-title":"Collagenase vs. placebo in the treatment of Peyronie\u2019s disease: a double blind study","volume":"149","author":"Gelbard","year":"1993","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2011.02.006_bib42","first-page":"180","article-title":"The use of intralesional clostridial collagenase injection therapy for Peyronie\u2019s disease: a prospective, single-center, non-placebo-controlled study","volume":"5","author":"Jordan","year":"2008","journal-title":"J\u00a0Sex Med"},{"issue":"5","key":"10.1016\/j.ucl.2011.02.006_bib43","first-page":"1209","article-title":"The use of collagenase in the treatment of Peyronie\u2019s disease M.K. Gelbard, A. Lindner, and J.J. Kaufman","volume":"4","author":"Glina","year":"2007","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2011.02.006_bib44","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1073\/pnas.93.11.5478","article-title":"Ca2+ channel blockers modulate metabolism of collagens within the extra-cellular matrix","volume":"93","author":"Roth","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.ucl.2011.02.006_bib45","first-page":"1522","article-title":"Intralesional verapamil injection for the treatment of Peyronie\u2019s disease","volume":"151","author":"Levine","year":"1994","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2011.02.006_bib46","first-page":"1395","article-title":"Treatment of Peyronie\u2019s disease with intralesional verapamil injection","volume":"158","author":"Levine","year":"1997","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2011.02.006_bib47","first-page":"621","article-title":"Experience with intraplaque injection of verapamil for Peyronie\u2019s disease","volume":"168","author":"Levine","year":"2002","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ucl.2011.02.006_bib48","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.urology.2007.02.042","article-title":"Intralesional verapamil prevents the progression of Peyronie\u2019s disease","volume":"69","author":"Bennett","year":"2007","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.ucl.2011.02.006_bib49","first-page":"2115","article-title":"An analysis of the natural history of Peyronie\u2019s disease","volume":"175","author":"Mulhall","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2011.02.006_bib50","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0090-4295(97)00700-0","article-title":"Use of intralesional verapamil to dissolve Peyronie\u2019s disease plaque: a long-term single-blind study","volume":"51","author":"Rehman","year":"1998","journal-title":"Urology"},{"issue":"11","key":"10.1016\/j.ucl.2011.02.006_bib51","first-page":"3743","article-title":"Nicardipine vs. saline injection as treatment for Peyronie\u2019s disease: a prospective, randomized, single-blind trial","volume":"7","author":"Soh","year":"2010","journal-title":"J\u00a0Sex Med"},{"issue":"3","key":"10.1016\/j.ucl.2011.02.006_bib52","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","article-title":"Effect of intralesional verapamil for treatment of Peyronie\u2019s disease: a randomized single-blind, placebo-controlled study","volume":"41","author":"Shirazi","year":"2009","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ucl.2011.02.006_bib53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/00365599109024539","article-title":"Regulation of the proliferation and biosynthetic activities of cultured human Peyronie\u2019s disease fibroblasts by interferons-alpha, -beta and -gamma","volume":"25","author":"Duncan","year":"1991","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.ucl.2011.02.006_bib54","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000475057","article-title":"Treatment of Peyronie\u2019s disease with local interferon-alpha-2b","volume":"28","author":"Wegner","year":"1995","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2011.02.006_bib55","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000480857","article-title":"Local inter-feron-alpha 2b is not an effective treatment in early-stage Peyronie\u2019s disease","volume":"32","author":"Wegner","year":"1997","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2011.02.006_bib56","first-page":"394","article-title":"Single-blind, multicenter placebo-controlled parallel study to asses the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie\u2019s disease","volume":"176","author":"Hellstrom","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2011.02.006_bib57","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.urology.2005.11.005","article-title":"Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie\u2019s disease: a randomized and prospective study","volume":"67","author":"Inal","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2011.02.006_bib58","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1038\/sj.ijir.3901084","article-title":"Review of current nonsurgical management of Peyronie\u2019s disease","volume":"15","author":"Levine","year":"2003","journal-title":"Int J Impot Res"},{"issue":"2","key":"10.1016\/j.ucl.2011.02.006_bib59","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.eururo.2009.05.012","article-title":"A\u00a0first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie\u2019s disease","volume":"56","author":"Palmieri","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2011.02.006_bib60","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1159\/000020359","article-title":"Extracorporeal shock wave therapy in the treatment of Peyronie\u2019s disease. First results of a case-controlled approach","volume":"38","author":"Hauck","year":"2000","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2011.02.006_bib61","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.urology.2009.03.017","article-title":"Effect of transdermal electromotive drug therapy on fibrogenic cytokine expression in Peyronie\u2019s disease","volume":"74","author":"Stancik","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2011.02.006_bib62","first-page":"972","article-title":"Verapamil versus saline in electromotive drug administration (EDMA) for Peyronie\u2019s disease: a double blind, placebo controlled trial","volume":"177","author":"Greenfield","year":"2007","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2011.02.006_bib63","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/archderm.1990.01670260092018","article-title":"Electrical stimulation and wound healing","volume":"126","author":"Weiss","year":"1990","journal-title":"Arch Dermatol"},{"issue":"9","key":"10.1016\/j.ucl.2011.02.006_bib64","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1046\/j.1464-410X.2003.04242.x","article-title":"Transdermal electromotive administration of verapamil and dexamethasone for Peyronie\u2019s disease","volume":"91","author":"Di Stasi","year":"2003","journal-title":"BJU Int"},{"issue":"119","key":"10.1016\/j.ucl.2011.02.006_bib65","doi-asserted-by":"crossref","first-page":"PE6","DOI":"10.1126\/stke.2002.119.pe6","article-title":"Mechanotransduction: all signals point to cytoskeleton, matrix, and integrins","volume":"2002","author":"Alenghat","year":"2002","journal-title":"Sci STKE"},{"issue":"1","key":"10.1016\/j.ucl.2011.02.006_bib66","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jor.1100130111","article-title":"Platelet-derived growth factor in fibrous musculoskeletal disorders: a study of pathologic tissue sections and in vitro primary cell cultures","volume":"13","author":"Alman","year":"1995","journal-title":"J\u00a0Orthop Res"},{"issue":"9","key":"10.1016\/j.ucl.2011.02.006_bib67","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2106\/00004623-199609000-00007","article-title":"The biochemical pathway mediating the proliferative response of bone cells to a mechanical stimulus","volume":"78","author":"Brighton","year":"1996","journal-title":"J\u00a0Bone Joint Surg Am"},{"issue":"3","key":"10.1016\/j.ucl.2011.02.006_bib68","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1054\/bjps.1997.3044","article-title":"Progressive skin extension: clinical and histological evaluation of a modified procedure using Kirschner wires","volume":"52","author":"Molea","year":"1999","journal-title":"Br J Plast Surg"},{"key":"10.1016\/j.ucl.2011.02.006_bib69","doi-asserted-by":"crossref","first-page":"53","DOI":"10.22203\/eCM.v015a05","article-title":"Bone development and its relation to fracture repair. The role of mesenchymal osteoblasts and surface osteoblasts","volume":"15","author":"Shapiro","year":"2008","journal-title":"Eur Cell Mater"},{"issue":"5","key":"10.1016\/j.ucl.2011.02.006_bib70","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/01.prs.0000182345.86453.4f","article-title":"Microarray analysis of mechanical shear effects on flexor tendon cells","volume":"116","author":"Fong","year":"2005","journal-title":"Plast Reconstr Surg"},{"issue":"3","key":"10.1016\/j.ucl.2011.02.006_bib71","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1586\/17434440.5.3.305","article-title":"FastSize Medical Extender for the treatment of Peyronie\u2019s disease","volume":"5","author":"Levine","year":"2008","journal-title":"Expert Rev Med Devices"},{"issue":"2","key":"10.1016\/j.ucl.2011.02.006_bib72","first-page":"558","article-title":"Use of penile extender device in the treatment of penile curvature as a result of Peyronie\u2019s disease. Results of a phase II prospective study","volume":"6","author":"Gontero","year":"2009","journal-title":"J\u00a0Sex Med"},{"issue":"pii","key":"10.1016\/j.ucl.2011.02.006_bib73","first-page":"37","article-title":"Penile traction therapy in Peyronie\u2019s disease","volume":"1","author":"Greenfield","year":"2009","journal-title":"F1000 Med Rep"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014311000206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014311000206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:23:39Z","timestamp":1758806619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014311000206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0094014311000206"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2011.02.006","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peyronie\u2019s Disease: Review of Nonsurgical Treatment Options","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2011.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}